Mukka Proteins

Why is Mukka Proteins Ltd falling/rising?

As of 11-Jun, Mukka Proteins Ltd's stock price is at 21.12, reflecting a decline of 0.71% and a total drop of 2.3% over the last two days. The stock has significantly underperformed, with year-to-date and annual declines of 12.04% and 34.00%, respectively, while trading below its moving averages, indicating a bearish trend.

As of 11-Jun, Mukka Proteins Ltd's stock price is falling, currently at 21.12, which reflects a decrease of 0.15 or 0.71%. The stock has underperformed its sector by 2.44% today and has been on a consecutive decline for the last two days, resulting in a total drop of 2.3% during this period. <BR><BR>In terms of performance over various time frames, the stock has experienced significant declines, with a 1-week drop of 3.83% and a 1-month decline of 12.37%. Year-to-date, the stock is down 12.04%, and over the past year, it has fallen by 34.00. This is in contrast to the benchmark Sensex, which has shown a smaller decline of 10.52% over the same period.<BR><BR>Additionally, Mukka Proteins is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. Investor participation has also decreased, with delivery volume falling by 11.29% compared to the 5-day average. Overall, these factors contribute to the stock's current downward trajectory.

Which are the latest news on Mukka Proteins?

What does Mukka Proteins do?

Mukka Proteins Ltd, a micro-cap company in the FMCG sector, was established in 2003 and reported net sales of ₹381 Cr and a net profit of ₹21 Cr for the quarter ending March 2026. Key financial metrics include a P/E ratio of 12.00 and a market cap of ₹654 Cr.

Overview:<BR>Mukka Proteins Ltd operates in the FMCG industry and is categorized as a micro-cap company.<BR><BR>History:<BR>Mukka Proteins Limited was originally incorporated as "Mukka Sea Food Industries" in Karnataka on March 13, 2003. The company transitioned from a partnership firm to a private company on November 04, 2010. The latest quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 381 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 21 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 654 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 12.00 <BR>Industry P/E: 22 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.44 <BR>Return on Equity: 10.37% <BR>Price to Book: 1.31 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is Mukka Proteins?

As of 10th June, Mukka Proteins Ltd has a market capitalization of 654.00 Cr, with net sales of 1449.46 Cr and a net profit of 51.77 Cr reported in the latest four quarters.

As of 10th June, Mukka Proteins Ltd has a market capitalization of 654.00 Cr, which classifies it as a Micro Cap company.<BR><BR>In the latest four quarters, Mukka Proteins reported net sales of 1449.46 Cr and a net profit of 51.77 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 440.70 Cr and total assets of 1,076.32 Cr.

Who are the peers of the Mukka Proteins?

Mukka Proteins' peers include Andrew Yule & Co, Lotus Chocolate, Vadilal Enterprises, Mcleod Russel, KSE, Euro India Fresh, Freshara Agro, and Proventus Agro. Mukka Proteins has a below-average growth and capital structure, with a 1-year return of -33.66%, better than Lotus Chocolate but lower than most peers.

Peers: The peers of Mukka Proteins are Andrew Yule & Co, Lotus Chocolate, Vadilal Enterp., Mcleod Russel, KSE, Euro India Fresh, Freshara Agro, and Proventus Agro.<BR><BR>Quality Snapshot: Below Average management risk is observed at Andrew Yule & Co, Mcleod Russel, Euro India Fresh, and Proventus Agro, while Average management risk is found at Lotus Chocolate, KSE, Freshara Agro, and Vadilal Enterp. Excellent growth is noted at Vadilal Enterp. and Freshara Agro, while Average growth is seen at Lotus Chocolate and KSE, and Below Average growth is present at Andrew Yule & Co, Mcleod Russel, Euro India Fresh, and Mukka Proteins. Excellent capital structure is attributed to KSE and Proventus Agro, while Average capital structure is noted at Vadilal Enterp. and Below Average at Andrew Yule & Co, Lotus Chocolate, Mcleod Russel, Euro India Fresh, Freshara Agro, and Mukka Proteins.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Apis India at 411.29%, while the lowest is Lotus Chocolate at -53.17%. Mukka Proteins has a 1-year return of -33.66%, which is higher than Lotus Chocolate but lower than most other peers. Additionally, the six-month return is negative for Andrew Yule & Co, KSE, and Mukka Proteins.

Are Mukka Proteins Ltd latest results good or bad?

Mukka Proteins Ltd's latest results are concerning, showing a 41.76% decline in Q4 FY26 net sales compared to the previous quarter, despite a 51.73% year-on-year increase in net profit. The company's heavy reliance on non-operating income and significant revenue volatility raise doubts about its long-term sustainability.

Mukka Proteins Ltd's latest results present a mixed picture, leaning more towards the negative side due to significant operational challenges. In Q4 FY26, the company reported net sales of ₹380.61 crores, which reflects a drastic decline of 41.76% compared to the previous quarter and a slight decrease of 0.25% year-on-year. This sharp drop follows an exceptional performance in Q3 FY26, where sales surged by 167.19%, indicating considerable volatility in revenue generation.<BR><BR>On the positive side, the consolidated net profit for Q4 FY26 was ₹20.62 crores, marking a year-on-year increase of 51.73%. The operating profit margin, excluding other income, improved to 9.21%, up from 7.84% in the same quarter last year. However, the company's heavy reliance on non-operating income, which constituted over 52% of profit before tax, raises concerns about the sustainability of these profit figures.<BR><BR>Overall, while there are some improvements in profitability metrics, the severe revenue volatility and negative operating cash flow—reported at ₹111 crores for FY25—highlight significant underlying issues. The stock has also underperformed compared to its peers and the broader FMCG sector, reflecting investor skepticism regarding its ability to deliver consistent value. Therefore, the latest results can be considered more concerning than encouraging.

Should I buy, sell or hold Mukka Proteins Ltd?

When is the next results date for Mukka Proteins Ltd?

The next results date for Mukka Proteins Ltd is 15 May 2026.

The next results date for Mukka Proteins Ltd is scheduled for 15 May 2026.

Is Mukka Proteins technically bullish or bearish?

As of December 3, 2025, Mukka Proteins is in a mildly bearish trend, supported by bearish daily moving averages and Bollinger Bands, despite some mixed signals from the MACD and RSI across different timeframes.

As of 3 December 2025, the technical trend for Mukka Proteins has changed from sideways to mildly bearish. The current stance is bearish, with key indicators supporting this view. The daily moving averages are bearish, and both the weekly and monthly Bollinger Bands are also bearish. Although the weekly MACD and KST are mildly bullish, the overall sentiment is tempered by the bearish signals from the moving averages and Bollinger Bands. The RSI shows no signal on the weekly timeframe, while it is bullish on the monthly, indicating mixed signals across different timeframes. Overall, the bearish trend is currently stronger, reflecting the recent price decline from the previous close.

Is Mukka Proteins overvalued or undervalued?

As of November 14, 2025, Mukka Proteins is considered very attractive and undervalued with a PE ratio of 16.74 and an EV to EBITDA of 12.74, outperforming peers like Avanti Feeds and Apex Frozen Foods, and has delivered an 8.16% return compared to the Sensex's 1.62%.

As of 14 November 2025, Mukka Proteins has moved from an attractive to a very attractive valuation grade. The company is currently considered undervalued, supported by a PE ratio of 16.74, an EV to EBITDA ratio of 12.74, and a PEG ratio of 0.00, indicating strong potential for growth relative to its price. <BR><BR>In comparison with peers, Avanti Feeds has a PE ratio of 16.54 and an EV to EBITDA of 10.04, while Apex Frozen Foods shows a significantly higher PE ratio of 43.53, suggesting that Mukka Proteins is positioned favorably within its industry. Additionally, the company's recent stock performance has outpaced the Sensex over the past week, with an 8.16% return compared to the Sensex's 1.62%, reinforcing the notion of its undervaluation.

How has been the historical performance of Mukka Proteins?

Mukka Proteins has shown fluctuating performance, with net sales declining to 1,006.42 Cr in March 2025 from 1,379.83 Cr in March 2024, alongside decreases in profitability, while total assets increased to 1,076.32 Cr. The company faced a challenging year marked by negative cash flow and reduced profits.

Answer:<BR>The historical performance of Mukka Proteins shows a fluctuating trend in net sales and profitability over the years, with a notable decline in the most recent fiscal year.<BR><BR>Breakdown:<BR>Mukka Proteins reported net sales of 1,006.42 Cr for the year ending March 2025, a decrease from 1,379.83 Cr in March 2024 and 1,177.12 Cr in March 2023, but an increase from 770.50 Cr in March 2022. Total operating income mirrored this trend, reaching 1,006.42 Cr in March 2025. The company's total expenditure, excluding depreciation, was 911.53 Cr in March 2025, down from 1,274.36 Cr in March 2024, while operating profit (PBDIT) was 110.01 Cr, showing a decline from 121.79 Cr in the previous year. Profit before tax also decreased to 59.20 Cr in March 2025 from 84.35 Cr in March 2024. Consequently, profit after tax fell to 47.03 Cr from 71.20 Cr. The company's total assets increased to 1,076.32 Cr in March 2025, up from 940.79 Cr in March 2024, and total liabilities also rose to 1,076.32 Cr from 940.79 Cr. Cash flow from operating activities remained negative at -111.00 Cr in March 2025, although cash and cash equivalents decreased to 3.00 Cr from 94.00 Cr in March 2024. Overall, Mukka Proteins experienced a challenging year with declining sales and profits, despite an increase in total assets and liabilities.

Who are the top shareholders of the Mukka Proteins?

The top shareholders of Mukka Proteins include Mohammed Haris K, who holds 30.23%, followed by 7 Foreign Institutional Investors with 2.63%, and Neomile Growth Fund - Series I with 1.98%. Individual investors own 19.85%, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Mukka Proteins include the promoters, who hold the majority of the shares. The promoter with the highest holding is Mohammed Haris K, who owns 30.23% of the company. Additionally, there are 7 Foreign Institutional Investors (FIIs) holding a combined 2.63% of the shares. The highest public shareholder is Neomile Growth Fund - Series I, which holds 1.98%. Individual investors collectively own 19.85% of the company. There are no pledged promoter holdings, and no mutual funds are currently invested in Mukka Proteins.

Has Mukka Proteins declared dividend?

No Dividend History Available